Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

AIDS

Volumn 11, Issue 4, 1997, Pages

  Merry, Concepta ^a,b   Barry, Michael G ^a   Mulcahy, Fiona ^b   Ryan, Mairin ^b   Heavey, Jane ^b   Tjia, John F ^a   Gibbons, Sara E ^a   Breckenridge, Alasdair M ^a   Back, David J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

Aids; HIV; Pharmacokinetics; Ritonavir; Saquinavir

Indexed keywords

ANTIVIRUS AGENT; RITONAVIR; SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL;

EID: 0031054507     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199704000-00001     Document Type: Article

References (21)

1. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 counts from 200-500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
2. Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
3. D'Aquila RT, Hughes MD, Johnson VA, et al.: Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996, 124:1019-1030.
4. Gulick R, Mellors J, Havlir D, et al.: Potent and sustained release antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC). Third Conférence on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract LB7].
5. Roberts NA: Drug resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 1995, 9 (suppl 2):S27-S32.
6. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
7. Markowitz M, Mo H, Kempf DK, et al.: Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995, 69:701-706.
8. Kumar GN, Rodrigues D, Buko AM, Denissen JF: Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996, 277:423-431.
9. Kempf D, Marsh K, Denissen J, et al.: Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract 143].
10. Hsu A, Granneman GR, Sun E, et al.: Assessment of single and multiple dose interactions between ritonavir and saquinavir. XI International Conference on AIDS. Vancouver, July 1996 [abstract LB-B6041].
11. Wrighton SA, Steven JC: The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992, 22:1-21
12. Sahai J: Risks and synergies from drug interactions, AIDS 1996, 10 (suppl 1):S21-S25.
13. Schapiro JM, Winters MA, Stewart F, et al.: The effect of high dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
14. Cameron DW, Hsu A, Granneman GR, et al.: Pharmacokinetics of ritonavir-saquinavir combination therapy [abstract]. AIDS 1996, 10 (suppl 2):S16.
15. Ouellet D, Hsu A, Granneman GR, et al.: Assessment of the pharmacokinetic interaction between ritonavir and clarithromycin [abstract]. Clin Pharmacol Ther 1996, 59:143.
16. Cato A, Cavanaugh JH, Shi H, Hsu A, Granneman GR, Leonard J: Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB1199].
17. Bertz RJ, Cao G, Cavanaugh JH, Hsu A, Granneman GR, Leonard JM: Effect of ritonavir on the pharmacokinetics of desipramine. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB1201].
18. Hsu A, Granneman GR, Witt G, Cavanaugh JH, Leonard J: Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB1200].
19. Ouellet D, Hsu A, Qian J, Cavanaugh J, Leonard J, Granneman GR: Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB1198].
20. Merry C, Ryan M, Mulcahy F, et al.: Tolerability of ritonavir and saquinavir during triple therapy for HIV infection [abstract]. AIDS 1996, 10 (suppl 2):S24.
21. Lea AP, Faulds D: Ritonavir. Drugs 1996, 52:541-548.